Corcept Therapeutics Incorporated (CORT) Sentiment Analysis
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
- ST sentiment gradeHow the market currently feels about this stock versus its peers
- A+
- Overall ST grade
- B
- ST Score
- 67.8
- Price change today
- —
- Strong buy
- —
- Buy
- —
- Hold
- —
- Sell
- —
- Strong sell
- —
- Bullish share0 bullish vs 0 bearish ratings
- —
Headline tone is a simple keyword scan of recent coverage, not a prediction.
CORT stock: frequently asked questions
What is CORT's ST Score?
Corcept Therapeutics Incorporated (CORT) has an ST Score of 67.8 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is CORT a buy, hold, or sell?
Analysts rate CORT a Buy, with a price target of $125.33 (+7.6% vs the current price). Our ST Score grades it B (67.8/100). The ST Score is a data-driven signal, not a recommendation.
What are CORT's factor grades?
Valuation D, Profitability A+, Financial Strength A-, Momentum A-, Growth B, Forecast C+, Sentiment A+.
What is CORT's valuation grade?
Corcept Therapeutics Incorporated (CORT) earns a valuation grade of D, measured against Medical - Pharmaceuticals peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is CORT's growth grade?
Corcept Therapeutics Incorporated (CORT) earns a growth grade of B, measured against Medical - Pharmaceuticals peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is CORT's profitability grade?
Corcept Therapeutics Incorporated (CORT) earns a profitability grade of A+, measured against Medical - Pharmaceuticals peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is CORT's financial strength grade?
Corcept Therapeutics Incorporated (CORT) earns a financial strength grade of A-, measured against Medical - Pharmaceuticals peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for CORT?
The average analyst price target for Corcept Therapeutics Incorporated (CORT) is $125.33 from 26 analysts, which is +7.6% versus the recent price of $116.45.
What is CORT's Piotroski score?
Corcept Therapeutics Incorporated (CORT) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.